Artificial intelligence and remote patient monitoring could help doctors catch heart damage caused by a common class of cancer drugs sooner, according to a narrative review published in the medical journal Cureus.
The review, titled "Early Detection of Anthracycline-Induced Cardiomyopathy: A Narrative Review of the Role of Artificial Intelligence and Remote Monitoring," focuses on anthracyclines — a widely used group of chemotherapy medicines. While effective against cancer, these drugs are known to carry a risk of damaging the heart muscle, a condition called cardiomyopathy.
As a narrative review, the Cureus paper surveys existing research rather than reporting a single new experiment. Its central theme is how two technologies — AI and remote monitoring — might be applied to spot this drug-related heart damage at an earlier stage, when it may be easier to manage.
Early detection matters in this setting because heart problems from cancer treatment can develop over time and may not be obvious until they become serious. Tools that continuously track patients away from the clinic, paired with AI that can flag subtle warning signs, represent an approach the authors examine for closing that gap.
The review reflects a broader trend at the intersection of oncology and cardiology, sometimes called cardio-oncology, where managing the heart-related side effects of cancer therapy is a growing concern.
Why it matters: For the many patients treated with anthracycline chemotherapy, technology that detects heart damage earlier could mean the difference between a manageable side effect and a life-altering complication.